Delayed gastric emptying and impaired gastric accommodation (decreased gastric compliance) play important roles in functional dyspepsia (FD). Here we screen for a clinically used drug with an ability to improve delayed gastric emptying in rats. Oral administration of aldioxa (dihydroxyaluminum allantoinate) partially improved clonidine- or restraint stress-induced delayed gastric emptying. Administration of allantoin, but not aluminium hydroxide, restored the gastric emptying. Both aldioxa and allantoin inhibited clonidine binding to the α-2 adrenergic receptor, suggesting that antagonistic activity of the allantoin moiety of aldioxa on this receptor is involved in the restoration of gastric emptying activity. Aldioxa or aluminium hydroxide but not allantoin restored gastric compliance with restraint stress, suggesting that aluminium hydroxide moiety is involved in this restoration. We propose that aldioxa is a candidate drug for FD, because its safety in humans has already been confirmed and its ameliorating effect on both of delayed gastric emptying and impaired gastric compliance are confirmed here.

Functional dyspepsia (FD), a functional gastrointestinal disorder, is characterized by persistent or recurrent postprandial upper abdominal discomfort and epigastric pain. The high prevalence of FD and associated healthcare costs suggests that treatment of this condition by methods other than prescribed medicines, such as natural products, could be beneficial. Delayed gastric emptying and impaired gastric accommodation play important roles in the development of FD. Anethole (1-methoxy-4-((E)-propenyl)-benzene), a major component of essential fennel oil, has been used as a flavoring, in alcoholic beverage production and in pharmaceutical formulations for many years. In this study, we examined the effects of anethole on delayed gastric emptying and impaired gastric accommodation in rodents. Oral administration of anethole improved clonidine-induced delayed gastric emptying but did not affect normal gastric emptying in mice. Fennel oil and Anchu-san (a Japanese herbal medicine containing anethole) also restored delayed gastric emptying. Furthermore, oral administration of anethole stimulated gastric accommodation in rats. These results suggest that anethole could be beneficial for the treatment of FD.

No abstract

Background: Recent progress in the treatment of multiple myeloma (MM) has improved its prognosis. However, the MM patients with high-risk cytogenetic abnormalities still showed significantly shorter survival. We have been focusing on komaroviquinone (KQN) which was isolated from Dracocephalum komarovi and had anti-tripanosomal activity. Since a number of anti-cancer drugs have been developed from natural products with anti-protozoal activities, we tried to examine anti-tumor effect of novel KQN-derivatives against high-risk MM cells. Results and Discussion: (1) Screening of KQN derivatives and the anti-myeloma activity: We screened total of 16 synthetic KQN-derivatives with regard to their ability to inhibit growth of MUM24 cells, established from a thalidomide resistant patient, harboring high-risk cytogenetic abnormalities such as t (4;14) and TP53 gene deletion. Two KQN-derivatives, GTN024 and GTN005 were found to inhibit proliferation of MUM24 (IC50: 3.29 µM, 16.25 µM, respectively). When MUM24 cells were co-cultured with 5µM GTN024 and 20µM GTN005, annexin-V-positive fraction significantly increased, suggesting that GTN024 and GTN005 induced apoptosis. (2) ROS production and anti-myeloma activity: Because GTN024 includes benzoquinone structure, we examined production of reactive oxygen species (ROS) by KQN-derivatives in MM cells. We found that GTN024 produced ROS and inhibited growth of MM cells, which was abrogated by pre-incubation with antioxidants. GTN005 does not have benzoquinone structure, and produced small amount of ROS. Its growth inhibitory activity did not change despite incubation of MUM24 cells with antioxidants. These results suggested that KQN-derivatives showed growth inhibition of MM cells via ROS production in GTN024 and ROS-independent mechanism in GTN005. (3) Toxicity of GTN024 and GTN005: To evaluate the effect of GTNs on normal hematopoiesis, we conducted colony formation assays using murine bone marrow cells. GTN024 significantly suppressed the production of total colonies of normal hematopoietic cells in 1µM or higher dose, but GTN005 did not inhibit the production of colonies in IC50 or higher dose. Therefore, GTN005 was not considered to be toxic to normal hematopoietic stem cells. (4) Structural optimization and anti-myeloma activity: To improve the ROS-independent anti-MM effect of GTN005, we modified the benzene ring which is a common structure of KQN-derivatives. We developed two new derivatives, GTN054 and GTN057, having 1,4-hydroxy benzene or 1-hydroxy-4-acetoxy benzene, respectively. These compounds significantly inhibited proliferation of MUM24 (IC50< 7µM). The results suggested that hydroxyl benzene structure was necessary for potent anti-MM effect. These two derivatives induced ROS production in MUM24 cells. However, growth inhibition did not change by pre-incubation with antioxidants. Therefore, anti-MM effects of GTN054 and GNT057 were independent of ROS production. (5)Anti-tumor effects in vivo: Intraperitoneal injections of GTN024 (10mg/kg BW) significantly delayed the growth of subcutaneous KMS11-derived plasmacytoma in SCID xenografts. When GTN024 was injected to mice in 20mg/kg BW or lower dose, no significant organ damages or hematological toxicity was observed. In higher dose, 40mg/kg BW, hematological toxicity was not observed, but gastrointestinal obstruction occurred. By pharmacokinetic analysis of GTN024, the Cmax was 392nM at 15min after injection of GTN024 and the half-life was 23min when 20mg/kg BW was injected. Conclusion: Our results implicated the possibility of KQN-derivatives as drugs for overcoming high-risk MM. Disclosures No relevant conflicts of interest to declare.

[Introduction] Recent development of novel drugs significantly improved prognosis of Multiple Myeloma (MM). Immunomodulatory drugs (IMiDs) and proteasome inhibitors play central roles in MM therapy. However expanded usage of lenalidomide (Len) has increased the number of Len-resistant patients. And limited information is obtainable with regand to Len-resistant mechanism, such as overexpression and genetic mutation of IMiDs-binding protein, celeblon (CRBN); thus, elucidating the Len-resistant mechanism and development of drugs overcoming the Len-resistance are very important for improving the outcome of MM. The purposes of this study are [1] to clarify the molecular mechanism of Len-resistance using Len-resistant MM cell lines [2] to confirm the mechanism of CRBN independent myeloma cell death by novel phthalimide-derivatives, TC11 and PEG(E)-TC11. [Method] [1] In our laboratory, Len-resistant cell lines, KMS21R, KMS27R and MUM24R have been established by long-term co-culture with low-dose Len. Using these cell lines, we examined expression of CRBN and the downstream molecules, IKZF1/3, IRF4 and c-MYC by western blotting. We also examined the mutation of CRBN in KMS27R. [2] We have originally developed a novel phthalimide-derivative, TC11 and PEG(E)-TC11 synthesized for improving water solubility. We examined whether TC11 and PEG(E)-TC11 induced cell death to Len-resistance MM or not. [Result] [1] First, we validated expression of CRBN and the down-stream molecules, which mediate pharmacological action of Len. Decreased expression of CRBN and subsequent up-regulation of down-stream IKZF1 were confirmed in KMS21R cell. In KMS27R cell, IKZF 1/3 expressions are increased without alteration of CRBN expression level. Thus, genetic mutation in CRBN or IKZF1 is suspected in KMS27R cells. In MUM24R cell, no significant change in the expression levels of the CRBN pathway molecules was confirmed, suggesting other molecular alternation than CRBN pathway. [2] TC11 significantly induced apoptosis of Len-resistant cells. We have previously reported that TC11 didn't bind to CRBN and TC11 directly bound to nucleophosmin1 (NPM1) and α-tubulin. It was found that TC11 induced G2/M arrest and subsequent apoptosis by inhibition of tubulin polymerization and NPM1 oligomerization. Fluorescence microscopy observation showed that TC11 treatment induced hyper duplication of centrosomes in MM cells. Water solubility and blood absorption of PEG(E)-TC11 were significantly improved compared with those of TC11. As a consequence, PEG-(E)TC11 significantly delayed tumor growth in xenograft model mice. [Discussion & Conclusion] [1] Our present data suggested diversity of Len-resistant mechanism in MM patients. For example, in KMS21R, decreased expression of CRBN was likely the cause of Len-resistance. In KMS27R, genetic mutation in CRBN-IKZF1 pathway caused inhibition of IKZF1 degradation. In MUM24R, the Len-resistant mechanism didn't relate to the CRBN pathway but to unknown molecular mechanism. Len-resistant cell lines are useful tools for studying Len-resistant mechanisms and developing drugs overcoming Len-resistance. [2]TC11 abrogated tubulin polymerization and NPM1 oligomerization, induced centrosome disruption and G2/M arrest. Since G2/M check point doesn't closely rely on p53. TC11 was able to induce apoptosis of MM cells with high-risk cytogenetic mutations such as deletion of TP53 gene. TC11 and PEG-(E)TC11 are expected as a candidate compound overcoming Len-resistance and high-risk MM. Disclosures Matsushita: Amgen: Research Funding. Hattori:Takeda: Research Funding; IDAC inc.: Research Funding.